VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement are significant for the biotechnology industry. By adopting FDA-aligned NAMs, VERAXA is positioning itself at the forefront of a regulatory shift toward more human-relevant and efficient preclinical testing methods. This could not only reduce the ethical and financial burdens associated with animal testing but also potentially speed up the delivery of new cancer therapies to patients. The reduction in preclinical cycle time and costs could enable VERAXA to allocate more resources to clinical development, enhancing its competitive edge.
For investors, this update signals VERAXA's commitment to innovation and efficiency, which could translate into faster pipeline progression and improved financial performance. The company's ability to demonstrate potent T cell-mediated killing with a fraction of the animal use underscores the robustness of its NAM approach and its potential to de-risk clinical trials. As regulatory agencies increasingly embrace NAMs, VERAXA's early adoption may serve as a model for other biotech firms.
To view the full press release, visit https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
